GGrantIndex
← Leaderboards

Karl Elmo Anderson

Massachusetts General Hospital

Google Scholar ↗PubMed ↗ORCID ↗
$6,471,926
Attributed
$7,281,487
Total exposure
29
Grants
21
Lead (contact PI)

Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.

Funding over time

peak $1M · FY2005–25
$2M$1.5M$1M$500K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25

Funding mix

By agency

NIH$3,658,338 · 26
FDA$3,623,149 · 3

By mechanism

R01$3,623,149 · 3
K30$2,247,802 · 2
M01$966,939 · 23
R21$443,597 · 1

Top collaborators

Most similar at Massachusetts General Hospital

Same institution · by research overlap

Others in their field

Top investigators on “Clinical Research”

Research focus

Clinical ResearchFundingResearch PersonnelGrantResourcesEnrollmentComputer Retrieval Of Information On Scientific Projects DatabaseUnited States National Institutes Of HealthSourceInstitutionHepatitis CPorphyriasPlasmaPorphyria Cutanea TardaEnzymesPorphyrinsMutationUrineEstrogensLeadTrainingFutureAlcohol ConsumptionSmoking

Grant awards (52)

Effect of Oral Cimetidine in the Protoporphyrias (IND 153247 submitted 9/2/2020)$313,713
R01 · FY2025 · FD
Effect of Oral Cimetidine in the Protoporphyrias (IND 153247 submitted 9/2/2020)$403,457
R01 · FY2024 · FD
Effect of Oral Cimetidine in the Protoporphyrias (IND 153247 submitted 9/2/2020)$403,457
R01 · FY2023 · FD
Effect of Oral Cimetidine in the Protoporphyrias (IND 153247 submitted 9/2/2020)$498,495
R01 · FY2021 · FD
Phase 2 Study of Hemin for Treatment and Prevention of Porphyria Attacks$207,571
R01 · FY2020 · FD · contact PI
Phase 2 Study of Hemin for Treatment and Prevention of Porphyria Attacks$397,570
R01 · FY2016 · FD · contact PI
Phase 2 Study of Hemin for Treatment and Prevention of Porphyria Attacks$392,992
R01 · FY2014 · FD · contact PI
Phase 2 Study of Hemin for Treatment and Prevention of Porphyria Attacks$339,537
R01 · FY2013 · FD · contact PI
Hydroxychloroquine vs Phlebotomy for PCT$66,335
R01 · FY2009 · FD · contact PI
CLINICAL TRIAL: HYDROXYCHLOROQUINE VS PHLEBOTOMY FOR PORPHYRIA CUTANEA TARDA$59,475
M01 · FY2009 · RR · contact PI
CLINICAL RESEARCH EDUCATION PROGRAM AT UTMB$50,000
K30 · FY2009 · RR · contact PI
Genetic Susceptibility Factors in Porphyria Cutanea Tarda (PCT)$47,777
R21 · FY2009 · DK · contact PI
GENETIC SUSCEPTIBILITY FACTORS IN PORPHYRIA CUTANEA TARDA (PCT)$17,843
M01 · FY2009 · RR · contact PI
CHARACTERIZATION OF ENZYME DEFECTS IN HUMAN PORPHYRIAS$10,159
M01 · FY2009 · RR · contact PI
Hydroxychloroquine vs Phlebotomy for PCT$304,445
R01 · FY2008 · FD · contact PI
CLINICAL RESEARCH EDUCATION PROGRAM AT UTMB$300,000
K30 · FY2008 · RR · contact PI
CLINICAL TRIAL: HYDROXYCHLOROQUINE VS PHLEBOTOMY FOR PORPHYRIA CUTANEA TARDA$284,465
M01 · FY2008 · RR · contact PI
GENETIC SUSCEPTIBILITY FACTORS IN PORPHYRIA CUTANEA TARDA (PCT)$99,624
M01 · FY2008 · RR · contact PI
CHARACTERIZATION OF ENZYME DEFECTS IN HUMAN PORPHYRIAS$19,873
M01 · FY2008 · RR · contact PI
CLINICAL RESEARCH EDUCATION PROGRAM AT UTMB$300,000
K30 · FY2007 · RR · contact PI
Genetic Susceptibility Factors in Porphyria Cutanea Tarda (PCT)$182,682
R21 · FY2007 · DK · contact PI
HYDROXYCHLOROQUINE VS PHLEBOTOMY FOR PORPHYRIA CUTANEA TARDA$69,993
M01 · FY2007 · RR · contact PI
BIOAVAILABILITY AND PHARMACOTHERAPEUTICS OF PROMETHAZINE IN HUMAN SUBJECTS$28,684
M01 · FY2007 · RR · contact PI
CHARACTERIZATION OF ENZYME DEFECTS IN HUMAN PORPHYRIAS$21,417
M01 · FY2007 · RR · contact PI
GENETIC SUSCEPTIBILITY FACTORS IN PORPHYRIA CUTANEA TARDA (PCT)$5,352
M01 · FY2007 · RR · contact PI
A MULTI-CENTER, DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED, PARALLEL GROUP$761
M01 · FY2007 · RR · contact PI
CYTOCHROME P450 ENZYMES IN HEPATITIS C OXIDATIVE INJURY$379
M01 · FY2007 · RR · contact PI
CLINICAL RESEARCH EDUCATION PROGRAM AT UTMB$300,000
K30 · FY2006 · RR · contact PI
Hydroxychloroquine vs Phlebotomy for PCT$295,577
R01 · FY2006 · FD · contact PI
Genetic Susceptibility Factors in Porphyria Cutanea Tarda (PCT)$213,138
R21 · FY2006 · DK · contact PI
BIOAVAILABILITY AND PHARMACOTHERAPEUTICS OF PROMETHAZINE IN HUMAN SUBJECTS$86,855
M01 · FY2006 · RR · contact PI
A MULTI-CENTER, DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED, PARALLEL GROUP$27,378
M01 · FY2006 · RR · contact PI
CYTOCHROME P450 ENZYMES IN HEPATITIS C OXIDATIVE INJURY$8,497
M01 · FY2006 · RR · contact PI
CHARACTERIZATION OF ENZYME DEFECTS IN HUMAN PORPHYRIAS$2,203
M01 · FY2006 · RR · contact PI
HYDROXYCHLOROQUINE VS PHLEBOTOMY FOR PORPHYRIA CUTANEA TARDA$630
M01 · FY2006 · RR · contact PI
CLINICAL RESEARCH EDUCATION PROGRAM AT UTMB$300,000
K30 · FY2005 · RR
BIOAVAILABILITY AND PHARMACOTHERAPEUTICS OF PROMETHAZINE IN HUMAN SUBJECTS$141,813
M01 · FY2005 · RR
CYTOCHROME P450 ENZYMES IN HEPATITIS C OXIDATIVE INJURY$20,005
M01 · FY2005 · RR
A MULTI-CENTER, DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED, PARALLEL GROUP$9,876
M01 · FY2005 · RR
CHARACTERIZATION OF ENZYME DEFECTS IN HUMAN PORPHYRIAS$1,266
M01 · FY2005 · RR
Hydroxychloroquine vs Phlebotomy for PCT$0
R01 · FY2005 · FD
CLINICAL RESEARCH EDUCATION PROGRAM AT UTMB$200,000
K30 · FY2004 · HL
Characterization of enzyme defects in human porphyrias$15,309
M01 · FY2004 · RR
Cytochrome P450 enzymes in hepatitis C oxidative injury$13,076
M01 · FY2004 · RR
A multi-center, double-blind, randomized, placebo-controlled, parallel group$8,930
M01 · FY2004 · RR
Bioavailability and pharmacotherapeutics of promethazine in human subjects$7,655
M01 · FY2004 · RR
Studies in porphyria III. Heme and tin mesoporphyrin in acute porphyrias$4,943
M01 · FY2004 · RR
Studies in porphyria VI: Pathogenesis of Porphyria Cutanea Tarda$478
M01 · FY2004 · RR
CLINICAL RESEARCH EDUCATION PROGRAM AT UTMB$200,000
K30 · FY2003 · HL
CLINICAL RESEARCH EDUCATION PROGRAM AT UTMB$200,000
K30 · FY2002 · HL
CLINICAL RESEARCH EDUCATION PROGRAM AT UTMB$200,000
K30 · FY2001 · HL
CLINICAL RESEARCH EDUCATION PROGRAM AT UTMB$197,802
K30 · FY2000 · HL